Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of HOT-1010 versus bevacizumab with carboplatin/paclitaxel in advanced non-squamous non-small cell lung cancer
CTR20202435Phase 3Active
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of HOT-1010 in non-small cell lung cancer (NSCLC), sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd.. Started Mar 2021; status: active.
02
Drugs
HOT-1010
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20202435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202435.